Fixed-dose combinations

Some pharmaceutical companies have produced fixed-dose combinations that contain two or more drugs in a single tablet. The currently licensed brand-name coformulations are:

  • Combivir: AZT + 3TC.
  • Kivexa: 3TC + abacavir.
  • Trizivir: AZT + 3TC + abacavir.
  • Truvada: tenofovir + emtricitabine.
  • Atripla: tenofovir + emtricitabine + efavirenz.
  • Kaletra: lopinavir + boosting dose of ritonavir.

Other fixed-dose coformulations containing these and other drugs are produced by generic drug manufacturers for use in resource-limited countries.

Fixed-dose combinations allow patients to take fewer pills. Atripla, for example, packs a complete two-class antiretroviral regimen into a single once-daily pill. In order to gain regulatory approval, companies must show that a fixed-dose tablet works as well as the separate drugs used together.

The drawback of fixed-dose combination pills is that the dosages of the individual drugs cannot be adjusted independently. This might be a problem, for example, if a person with kidney disease needs to take a lower than usual dose of tenofovir. For such people, using the separate pills may be a better option.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap